Business Context and Reporting Period
Company: Gain Therapeutics, Inc. (GANX)
Filing Type: Form 8-K (Current Report)
Date of Report: June 30, 2025
Subject: Update on the Phase 1b clinical study of GT-02287 for Parkinson's Disease.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial progress and operational updates.
Material Changes and Clinical Progress
- Enrollment Status: The Phase 1b study reached 16 participants by June 30, 2025, meeting the target range of 15-20 despite a two-month protocol implementation delay.
- Safety Update: The independent data monitoring committee recommended continuing the study with no dose changes, noting no serious treatment-emergent adverse events.
- Timeline Acceleration: Due to faster-than-anticipated enrollment, 90-day visits will conclude in time for biomarker analysis in Q4 2025, rather than the originally planned Q1 2026.
- Results Expectation: Full results on 90-day biomarker evidence (CSF and blood) are expected in Q4 2025.
Outlook, Management Commentary, and Future Plans
- Study Extension: The screening window for participants in Australia is extended through July 31, 2025.
- Protocol Modification: The Company plans to approach Australian health authorities to extend the dosing period beyond the current 90-day limit to better inform Phase 2 protocol design for early 2026.
- Toxicology Status: Long-term chronic toxicology studies required to support the dosing extension are near completion.
- Next Update: An update on the progress of the dosing extension is expected before the end of Q3 2025.
Investor Verification Checklist
- Confirm the exact date of the Q4 2025 data readout for GT-02287 biomarker results.
- Verify the regulatory status of the proposed dosing extension in Australia.
- Monitor the completion status of long-term chronic toxicology studies required for the protocol extension.
- Review the Phase 2 protocol design timeline scheduled for early 2026.